Literature DB >> 7749161

In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers.

W Zoli1, A Flamigni, G L Frassineti, P Bajorko, F De Paola, C Milandri, D Amadori, A Gasperi-Campani.   

Abstract

The in vitro activities of taxol and taxotere in comparison with cisplatin and doxorubicin were assessed in 30 primary tumor cultures from human breast cancers. Both taxanes were much more potent than cisplatin and doxorubicin. Taxotere was 3.1; 296, and 9.6-fold more cytotoxic than taxol, cisplatin, and doxorubicin respectively. The cytotoxic activity observed in our experiments confirms the potential clinical relevance of the two taxanes in the management of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7749161     DOI: 10.1007/BF00666492

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  23 in total

1.  Potentials of cell kinetics in the management of patients with ovarian cancers.

Authors:  R Silvestrini; M G Daidone; B Valentinis; C Ferraris; E Di Re; F Raspagliesi; F Landoni; G Scarfone; G Bolis
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

2.  Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.

Authors:  M C Bissery; D Guénard; F Guéritte-Voegelein; F Lavelle
Journal:  Cancer Res       Date:  1991-09-15       Impact factor: 12.701

3.  Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute.

Authors: 
Journal:  Eur J Cancer       Date:  1980-11       Impact factor: 9.162

4.  Relationships between the structure of taxol analogues and their antimitotic activity.

Authors:  F Guéritte-Voegelein; D Guénard; F Lavelle; M T Le Goff; L Mangatal; P Potier
Journal:  J Med Chem       Date:  1991-03       Impact factor: 7.446

5.  Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.

Authors:  L R Kelland; G Abel
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion.

Authors:  D Bissett; A Setanoians; J Cassidy; M A Graham; G A Chadwick; P Wilson; V Auzannet; N Le Bail; S B Kaye; D J Kerr
Journal:  Cancer Res       Date:  1993-02-01       Impact factor: 12.701

7.  Preliminary correlations of clinical outcome with in vitro chemosensitivity of second passage human breast cancer cells.

Authors:  H S Smith; W Zoli; A Volpi; A Hiller; M Lippman; S Swain; B Mayall; C Dollbaum; A J Hackett; D Amadori
Journal:  Cancer Res       Date:  1990-05-15       Impact factor: 12.701

8.  Phase I trial of taxol in patients with advanced cancer.

Authors:  R C Donehower; E K Rowinsky; L B Grochow; S M Longnecker; D S Ettinger
Journal:  Cancer Treat Rep       Date:  1987-12

9.  Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents.

Authors:  M Vogel; S G Hilsenbeck; H Depenbrock; S Danhauser-Riedl; T Block; H Nekarda; C Fellbaum; M S Aapro; M C Bissery; J Rastetter
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

10.  In vitro cytotoxic activity of Taxol and Taxotere on primary cultures and established cell lines of human ovarian cancer.

Authors:  R Silvestrini; N Zaffaroni; L Orlandi; S Oriana
Journal:  Stem Cells       Date:  1993-11       Impact factor: 6.277

View more
  4 in total

1.  Prospective phase II study of neoadjuvant doxorubicin followed by cisplatin/docetaxel in locally advanced breast cancer.

Authors:  Taher A Al-Tweigeri; Dahish S Ajarim; Adher A Alsayed; Mohamed M Rahal; Mohamed O Alshabanah; Asma M Tulbah; Osama A Al-Malik; Doha M Fatani; Gamal A El-Husseiny; Naser B Elkum; Adnan A Ezzat
Journal:  Med Oncol       Date:  2009-06-13       Impact factor: 3.064

2.  A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers.

Authors:  Joseph Baar; Paula Silverman; Janice Lyons; Pingfu Fu; Fadi Abdul-Karim; Nicholas Ziats; Jay Wasman; Paul Hartman; John Jesberger; Leda Dumadag; Erin Hohler; Rosemary Leeming; Robert Shenk; Helen Chen; Keith McCrae; Afshin Dowlati; Scot C Remick; Beth Overmoyer
Journal:  Clin Cancer Res       Date:  2009-05-05       Impact factor: 12.531

Review 3.  Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer.

Authors:  B Fulton; C M Spencer
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

4.  Mathematical characterization of population dynamics in breast cancer cells treated with doxorubicin.

Authors:  Emily Y Yang; Grant R Howard; Amy Brock; Thomas E Yankeelov; Guillermo Lorenzo
Journal:  Front Mol Biosci       Date:  2022-09-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.